** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with "buy" rating and $20 PT, a 251.5% upside to the stock's last close
** Says co's Alzheimer's disease drug Zunveyl, which is a "next-generation symptomatic therapy" has been shown to have a "very low rate of GI side effects (only 1-2%)" compared to 30-40% with existing cholinesterase inhibitors, and "eliminate sleep disturbances"
** Says co has a "finely tuned sales force" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl
** Co has a "considerable long-term promise" that is not reflected in its current stock price, which has been "range-bound" due to its relatively unknown status among US investors - brokerage
** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s
** Stock fell ~53% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。